Brokerages Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have been assigned an average rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $38.3333.

PHAR has been the subject of several recent research reports. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Oppenheimer reiterated an “outperform” rating and set a $41.00 target price (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Tuesday, March 24th. Finally, Weiss Ratings upgraded Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, April 27th.

Hedge Funds Weigh In On Pharming Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC boosted its stake in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the last quarter. Millennium Management LLC bought a new position in Pharming Group during the fourth quarter worth $360,000. SmartHarvest Portfolios LLC bought a new position in Pharming Group during the fourth quarter worth $224,000. Finally, EverSource Wealth Advisors LLC bought a new position in Pharming Group during the second quarter worth $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Stock Down 1.0%

Shares of NASDAQ:PHAR opened at $12.85 on Tuesday. The company has a quick ratio of 2.06, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. Pharming Group has a 52-week low of $8.69 and a 52-week high of $21.34. The company has a 50 day moving average of $16.13 and a two-hundred day moving average of $16.55. The company has a market capitalization of $907.40 million, a price-to-earnings ratio of 80.31 and a beta of 0.04.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The firm had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. As a group, analysts forecast that Pharming Group will post 0.38 earnings per share for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.